ALT5 Sigma Corporation was founded in Minnesota in 1983. In 2018, the company was re-registered in Nevada. The company is committed to being a clinical-stage pharmaceutical company dedicated to finding treatments for conditions that cause severe pain and bringing drugs with non-addictive analgesic properties to market. One of the company's goals is to reduce the need for dangerous opioid prescriptions by treating underlying conditions that cause severe pain. The company's first drug candidate is a treatment for peripheral arterial disease, which causes severe pain and affects more than 8.5 million people in the United States. 

ALTS

ALTS Profile